Role of C-reactive protein in cerebrovascular disease: A critical review

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 12, 2011, Pages 1565-1584

  Di Napoli, Mario ^a,b   Elkind, Mitchell Sv ^c   Godoy, Daniel Agustin ^d   Singh, Puneetpal ^e   Papa, Francesca ^b   Popa Wagner, Aurel ^f,g  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b SMDN   (Italy)

^c Department of Medicine   (United States)

^d Neurocritical Care Unit Sanatorio Pasteur   (Argentina)

^e PUNJABI UNIVERSITY   (India)

^f UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^g UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

C reactive protein; cerebral ischemia; cerebrovascular disease; inflammation; intracerebral hemorrhage; stroke

Indexed keywords

C REACTIVE PROTEIN; FC RECEPTOR;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; COMPLEMENT ACTIVATION; HUMAN; LIGAND BINDING; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

AGING; ANIMALS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBROVASCULAR DISORDERS; COMPLEMENT ACTIVATION; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; PHAGOCYTES; PROGNOSIS; PROTEIN CONFORMATION; RECEPTORS, IGG;

EID: 82755161174     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.159     Document Type: Review

References (206)

1. Lloyd-Jones D, Adams RJ, Brown TM et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121(7), 948-954 (2010).
2. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121(7), e46-e215 (2010).
3. Di Napoli M, Papa F. Neuroinflammation. An important role in the pathogenic pathways of cerebral ischemia. Nova Science Publishers, Inc., NY, USA (2009).
4. Wang J, Dore S. Inflammation after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 27(5), 894-908 (2007). (Pubitemid 46659028)
5. Pradilla G, Chaichana KL, Hoang S, Huang J, Tamargo RJ. Inflammation and cerebral vasospasm after subarachnoid hemorrhage. Neurosurg. Clin. N. Am. 21(2), 365-379 (2010).
6. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 38(2-3), 189-197 (2001). (Pubitemid 32786776)
7. Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A. Pattern recognition by pentraxins. Adv. Exp. Med. Biol. 653, 98-116 (2009).
8. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7(2), 169-177 (1999). (Pubitemid 29159702)
9. Shrive AK, Cheetham GM, Holden D et al. Three dimensional structure of human C-reactive protein. Nat. Struct. Biol. 3(4), 346-354 (1996). (Pubitemid 26112633)
10. Mikolajek H, Kolstoe SE, Pye VE, Mangione P, Pepys MB, Wood SP. Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component. J. Mol. Recognit. 24(2), 371-377 (2011).
11. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 111(12), 1805-1812 (2003). (Pubitemid 38057722)
12. Das T, Mandal C. Variations in binding characteristics of glycosylated human C-reactive proteins in different pathological conditions. Glycoconj. J. 20(9), 537-543 (2004). (Pubitemid 41406510)
13. Das T, Sen AK, Kempf T, Pramanik SR, Mandal C. Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem. J. 373(Pt 2), 345-355 (2003). (Pubitemid 36897838)
14. Lu J, Marnell LL, Marjon KD, Mold C, du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 456(7224), 989-992 (2008).
15. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 332(6166), 738-740 (1988).
16. Mcgrath FD, Brouwer MC, Arlaud GJ, Daha MR, Hack CE, Roos A. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J. Immunol. 176(5), 2950-2957 (2006).
17. Gaboriaud C, Juanhuix J, Gruez A et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J. Biol. Chem. 278(47), 46974-46982 (2003). (Pubitemid 37452280)
18. Kinoshita CM, Ying SC, Hugli TE et al. Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry 28(25), 9840-9848 (1989). (Pubitemid 20022333)
19. Bang R, Marnell L, Mold C et al. Analysis of binding sites in human C-reactive protein for Fc{gamma}RI, Fc{gamma} RIIA, and C1q by site-directed mutagenesis. J. Biol. Chem. 280(26), 25095-25102 (2005). (Pubitemid 40934601)
20. Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE. Topology and structure of the C1q-binding site on C-reactive protein. J. Immunol. 166(6), 3998-4004 (2001). (Pubitemid 32224928)
21. Ji SR, Wu Y, Zhu L et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J. 21(1), 284-294 (2007). (Pubitemid 46052567)
22. Eisenhardt SU, Habersberger J, Murphy A et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ. Res. 105(2), 128-137 (2009).
23. Ying SC, Gewurz H, Kinoshita CM, Potempa LA, Siegel JN. Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. J. Immunol. 143(1), 221-228 (1989). (Pubitemid 19174224)
24. Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109(16), 2016-2022 (2004 (Pubitemid 38544493)
25. Khreiss T, Jozsef L, Potempa LA, Filep JG. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 110(17), 2713-2720 (2004). (Pubitemid 39453024)
26. Khreiss T, Jozsef L, Potempa LA, Filep JG. Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ. Res. 97(7), 690-697 (2005). (Pubitemid 41416338)
27. Molins B, Pena E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler. Thromb. Vasc. Biol. 28(12), 2239-2246 (2008).
28. Rees RF, Gewurz H, Siegel JN, Coon J, Potempa LA. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle. Clin. Immunol. Immunopathol. 48(1), 95-107 (1988).
29. Slevin M, Krupinski J. A role for monomeric C-reactive protein in regulation of angiogenesis, endothelial cell inflammation and thrombus formation in cardiovascular/cerebrovascular disease? Histol. Histopathol. 24(11), 1473-1478 (2009).
30. Volanakis JE, Narkates AJ. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J. Immunol. 126(5), 1820-1825 (1981). (Pubitemid 11120965)
31. Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, Van Den Bosch H. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol. Today 18(3), 111-115 (1997). (Pubitemid 27087298)
32. Li YP, Mold C, Du Clos TW. Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J. Immunol. 152(6), 2995-3005 (1994). (Pubitemid 24097998)
33. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc. Natl Acad. Sci. USA 99(20), 13043-13048 (2002).
34. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J. Exp. Med. 192(9), 1353-1364 (2000).
35. Hart SP, Alexander KM, Maccall SM, Dransfield I. C-reactive protein does not opsonize early apoptotic human neutrophils, but binds only membrane-permeable late apoptotic cells and has no effect on their phagocytosis by macrophages. J. Inflamm. (Lond.) 2, 5 (2005).
36. Black S, Kushner I, Samols D. C-reactive Protein. J. Biol. Chem. 279(47), 48487-48490 (2004). (Pubitemid 39625721)
37. Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. Int. Rev. Exp. Pathol. 27, 83-111 (1985). (Pubitemid 15060290)
38. Rowe IF, Soutar AK, Trayner IM, Thompson GR, Pepys MB. Circulating human C-reactive protein binds very low density lipoproteins. Clin. Exp. Immunol. 58(1), 237-244 (1984). (Pubitemid 14029148)
39. Vigo C. Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. J. Biol. Chem. 260(6), 3418-3422 (1985). (Pubitemid 15115258)
40. Robey FA, Jones KD, Tanaka T, Liu TY. Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J. Biol. Chem. 259(11), 7311-7316 (1984). (Pubitemid 14077816)
41. Du Clos TW, Marnell L, Zlock LR, Burlingame RW. Analysis of the binding of C-reactive protein to chromatin subunits. J. Immunol. 146(4), 1220-1225 (1991).
42. Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol. Biol. Rep. 23(3-4), 253-260 (1996). (Pubitemid 27153049)
43. Du Clos TW. Function of C-reactive protein. Ann. Med. 32(4), 274-278 (2000). (Pubitemid 30311864)
44. Black S, Agrawal A, Samols D. The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct. Mol. Immunol. 39(16), 1045-1054 (2003). (Pubitemid 36577124)
45. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 42(1-3), 23-30 (1999). (Pubitemid 29322284)
46. Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology and host defense function. Clin. Chem. Lab. Med. 37(3), 265-270 (1999). (Pubitemid 29209739)
47. Volanakis JE, Narkates AJ. Binding of human C4 to C-reactive protein-pneumococcal C-polysaccharide complexes during activation of the classical complement pathway. Mol. Immunol. 20(11), 1201-1207 (1983). (Pubitemid 14230029)
48. Li SH, Szmitko PE, Weisel RD et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 109(7), 833-836 (2004). (Pubitemid 38252733)
49. Okemefuna AI, Nan R, Miller A, Gor J, Perkins SJ. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J. Biol. Chem. 285(2), 1053-1065 (2010).
50. Hakobyan S, Harris CL, Van Den Berg CW et al. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J. Biol. Chem. 283(45), 30451-30460 (2008).
51. Tron K, Manolov DE, Rocker C, Kachele M, Torzewski J, Nienhaus GU. C-reactive protein specifically binds to Fcgamma receptor type I on a macrophage-like cell line. Eur. J. Immunol. 38(5), 1414-1422 (2008).
52. Stein MP, Mold C, Du Clos TW. C-reactive protein binding to murine leukocytes requires Fc gamma receptors. J. Immunol. 164(3), 1514-1520 (2000). (Pubitemid 30067268)
53. Lu J, Marjon KD, Marnell LL et al. Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein. Proc. Natl Acad. Sci. USA 108(12), 4974-4979 (2011).
54. Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-reactive protein binds to Fc gamma RI in transfected COS cells. J. Immunol. 155(4), 2185-2193 (1995).
55. Bodman-Smith KB, Melendez AJ, Campbell I, Harrison PT, Allen JM, Raynes JG. C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcgammaRI). Immunology 107(2), 252-260 (2002). (Pubitemid 35279052)
56. Manolov DE, Rocker C, Hombach V, Nienhaus GU, Torzewski J. Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcgammaRIIa. Arterioscler. Thromb. Vasc. Biol. 24(12), 2372-2377 (2004). (Pubitemid 39658044)
57. Agrawal A, Volanakis JE. Probing the C1q-binding site on human C-reactive protein by site-directed mutagenesis. J. Immunol. 152(11), 5404-5410 (1994). (Pubitemid 24152989)
58. Hundt M, Zielinska-Skowronek M, Schmidt RE. Lack of specific receptors for C-reactive protein on white blood cells. Eur. J. Immunol. 31(12), 3475-3483 (2001). (Pubitemid 34030960)
59. Salmon JE, Pricop L. Human receptors for immunoglobulin G: key elements in thepathogenesis of rheumatic disease. Arthritis Rheum. 44(4), 739-750 (2001). (Pubitemid 32319766)
60. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103(9), 1194-1197 (2001). (Pubitemid 32221339)
61. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44(1), 6-11 (2004). (Pubitemid 38823477)
62. Devaraj S, Dasu MR, Singh U, Rao LV, Jialal I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 203(1), 67-74 (2009).
63. Trachtman H, Futterweit S, Arzberger C et al. Nitric oxide and superoxide in rat mesangial cells: modulation by C-reactive protein. Pediatr. Nephrol. 21(5), 619-626 (2006).
64. Han KH, Hong KH, Park JH et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 109(21), 2566-2571 (2004). (Pubitemid 38720558)
65. Nagai T, Anzai T, Kaneko H et al. C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension 57(2), 208-215 (2011).
66. Nunomura W. C-reactive protein in eel: purification and agglutinating activity. Biochim. Biophys. Acta 1076(2), 191-196 (1991).
67. Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178(5), 1629-1636 (1993). (Pubitemid 23318441)
68. Boncler M, Luzak B, Rozalski M, Golanski J, Rychlik B, Watala C. Acetylsalicylic acid is compounding to antiplatelet effect of C-reactive protein. Thromb. Res. 119(2), 209-216 (2007). (Pubitemid 44765069)
69. Zouki C, Beauchamp M, Baron C, Filep JG. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of l-selectin by C-reactive protein and peptides derived from C-reactive protein. J. Clin. Invest. 100(3), 522-529 (1997). (Pubitemid 27340498)
70. Kindmark CO. In vitro binding of human C-reactive protein by some pathogenic bacteria and zymosan. Clin. Exp. Immunol. 11(2), 283-289 (1972).
71. Diaz Padilla N, Bleeker WK, Lubbers Y et al. Rat C-reactive protein activates the autologous complement system. Immunology 109(4), 564-571 (2003). (Pubitemid 36930173)
72. Boncler M, Rywaniak J, Szymanski J, Potempa LA, Rychlik B, Watala C. Modified C-reactive protein interacts with platelet glycoprotein Ibalpha. Pharmacol. Rep. 63(2), 464-475 (2011).
73. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler. Thromb. Vasc. Biol. 25(10), 2216-2221 (2005). (Pubitemid 41416324)
74. Yavin EJ, Fridkin M. Peptides derived from human C-reactive protein inhibit the enzymatic activities of human leukocyte elastase and cathepsin G: use of overlapping peptide sequences to identify a unique inhibitor. J. Pept. Res. 51(4), 282-289 (1998). (Pubitemid 28136041)
75. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 8(12), 3773-3779 (1989). (Pubitemid 20016058)
76. Yap SH, Moshage HJ, Hazenberg BP et al. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim. Biophys. Acta 1091(3), 405-408 (1991).
77. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin. Chem. 48, 111-136 (2009).
78. Ramage L, Guy K. Expression of C-reactive protein and heat-shock protein-70 in the lung epithelial cell line A549, in response to PM10 exposure. Inhal. Toxicol. 16(6-7), 447-452 (2004). (Pubitemid 38685136)
79. Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 68(5), 2103-2110 (2005). (Pubitemid 43117784)
80. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108(16), 1930-1932 (2003). (Pubitemid 37296536)
81. Jabs WJ, Theissing E, Nitschke M et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 108(12), 1428-1431 (2003). (Pubitemid 37176446)
82. Yasojima K, Schwab C, McGeer EG, Mcgeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol. 158(3), 1039-1051 (2001). (Pubitemid 32221796)
83. Lu Q, Jin L. Human gingiva is another site of C-reactive protein formation. J. Clin. Periodontol. 37(9), 789-796 (2010).
84. Yasojima K, Schwab C, Mcgeer EG, Mcgeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimers disease. Brain Res. 887(1), 80-89 (2000). (Pubitemid 32008026)
85. Mulder SD, Hack CE, Van Der Flier WM, Scheltens P, Blankenstein MA, Veerhuis R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimers disease with the use of index values. J. Alzheimers Dis. 22(4), 1073-1079 (2010).
86. Stearman M, Southgate HJ. The use of cytokine and C-reactive protein measurements in cerebrospinal fluid during acute infective meningitis. Ann. Clin. Biochem. 31(Pt 3), 255-261 (1994). (Pubitemid 24167829)
87. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340(6), 448-454 (1999). (Pubitemid 29084777)
88. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology 23(2), 118-124 (1991).
89. Kushner I, Broder ML, Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J. Clin. Invest. 61(2), 235-242 (1978). (Pubitemid 8280392)
90. King DE, Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. Am. J. Cardiol. 92(11), 1335-1339 (2003). (Pubitemid 37431147)
91. Ford ES, Giles WH, Myers GL, Rifai N, Ridker PM, Mannino DM. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin. Chem. 49(8), 1353-1357 (2003). (Pubitemid 36900622)
92. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin. Chem. 50(3), 574-581 (2004 (Pubitemid 38297308)
93. Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin. Chem. 46(7), 934-938 (2000). (Pubitemid 30461263)
94. Davis EE, Huffman FG. Differences in coronary heart disease risk markers among apparently healthy individuals of African ancestry. J. Natl Med. Assoc. 99(6), 658-664 (2007). (Pubitemid 47012776)
95. Chambers JC, Eda S, Bassett P et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 104(2), 145-150 (2001). (Pubitemid 32655829)
96. Saito I, Sato S, Nakamura M et al. A low level of C-reactive protein in Japanese adults and its association with cardiovascular risk factors: the Japan NCVC-Collaborative Inflammation Cohort (JNIC) study. Atherosclerosis 194(1), 238-244 (2007). (Pubitemid 47464303)
97. Wen J, Liang Y, Wang F et al. Association of C-reactive protein and metabolic syndrome in a rural Chinese population. Clin. Biochem. 42(10-11), 976-983 (2009).
98. Mcdade TW, Rutherford J, Adair L, Kuzawa CW. Early origins of inflammation: microbial exposures in infancy predict lower levels of C-reactive protein in adulthood. Proc. Biol. Sci. 277(1684), 1129-1137 (2010).
99. Imhof A, Frohlich M, Loewel H et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin. Chem. 49(4), 669-672 (2003). (Pubitemid 36379539)
100. Yamada S, Gotoh T, Nakashima Y et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am. J. Epidemiol. 153(12), 1183-1190 (2001). (Pubitemid 32552276)
101. Stork S, Bots ML, Grobbee DE, Van Der Schouw YT. Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J. Intern. Med. 264(3), 245-253 (2008).
102. Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J. Rheumatol. 27(10), 2351-2359 (2000).
103. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am. J. Cardiol. 89(9), 1117-1119 (2002). (Pubitemid 34462860)
104. Tracy RP, Psaty BM, Macy E et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler. Thromb. Vasc. Biol. 17(10), 2167-2176 (1997). (Pubitemid 28057118)
105. Kershaw KN, Mezuk B, Abdou CM, Rafferty JA, Jackson JS. Socioeconomic position, health behaviors, and C-reactive protein: a moderated-mediation analysis. Health Psychol. 29(3), 307-316 (2010).
106. Aiello AE, Kaplan GA. Socioeconomic position and inflammatory and immune biomarkers of cardiovascular disease: applications to the Panel Study of Income Dynamics. Biodemography Soc. Biol. 55(2), 178-205 (2009).
107. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am. J. Med. 119(2), 166.e117-e128 (2006).
108. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J. Intern. Med. 264(4), 295-314 (2008).
109. Glynn RJ, Macfadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin. Chem. 55(2), 305-312 (2009).
110. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347), 317-325 (2011).
111. Crawford DC, Yi Q, Smith JD et al. Allelic spectrum of the natural variation in CRP. Hum. Genet. 119(5), 496-504 (2006).
112. Hage FG, Szalai AJ. The role of C-reactive protein polymorphisms in inflammation and cardiovascular risk. Curr. Atheroscler. Rep. 11(2), 124-130 (2009).
113. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J. Clin. Endocrinol. Metab. 88(1), 255-259 (2003). (Pubitemid 36115175)
114. Lakka HM, Lakka TA, Rankinen T et al. The TNF-alpha G-308A polymorphism is associated with C-reactive protein levels: the HERITAGE Family Study. Vascul. Pharmacol. 44(5), 377-383 (2006).
115. Ridker PM, Pare G, Parker A et al. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Womens Genome Health Study. Am. J. Hum. Genet. 82(5), 1185-1192 (2008).
116. Ben-Assayag E, Shenhar-Tsarfaty S, Bova I et al. Triggered C-reactive protein (CRP) concentrations and the CRP gene -717A>G polymorphism in acute stroke or transient ischemic attack. Eur. J. Neurol. 14(3), 315-320 (2007). (Pubitemid 46384870)
117. Bis JC, Heckbert SR, Smith NL et al. Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis 198(1), 166-173 (2008). (Pubitemid 351406372)
118. Flex A, Gaetani E, Papaleo P et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 35(10), 2270-2275 (2004). (Pubitemid 39311248)
119. Grocott HP, White WD, Morris RW et al. Genetic polymorphisms and the risk of stroke after cardiac surgery. Stroke 36(9), 1854-1858 (2005). (Pubitemid 41266513)
120. Ladenvall C, Jood K, Blomstrand C, Nilsson S, Jern C, Ladenvall P. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke 37(8), 2018-2023 (2006). (Pubitemid 44309897)
121. Lange LA, Carlson CS, Hindorff LA et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 296(22), 2703-2711 (2006). (Pubitemid 44917547)
122. Liu ZZ, Lv H, Gao F et al. Polymorphism in the human C-reactive protein (CRP) gene, serum concentrations of CRP, and the difference between intracranial and extracranial atherosclerosis. Clin. Chim. Acta 389(1-2), 40-44 (2008).
123. Miller DT, Zee RY, Suk Danik J et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann. Hum. Genet. 69(Pt 6), 623-638 (2005). (Pubitemid 41556317)
124. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 178(1), 139-145 (2005 (Pubitemid 39600826)
125. Wang Q, Ding H, Tang JR et al. C-reactive protein polymorphisms and genetic susceptibility to ischemic stroke and hemorrhagic stroke in the Chinese Han population. Acta Pharmacol. Sin. 30(3), 291-298 (2009).
126. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359(18), 1897-1908 (2008).
127. Fornage M, Chiang YA, OMeara ES et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: the Cardiovascular Health Study. Stroke 39(7), 1952-1959 (2008).
128. Morita A, Nakayama T, Soma M. Association study between C-reactive protein genes and ischemic stroke in Japanese subjects. Am. J. Hypertens. 19(6), 593-600 (2006). (Pubitemid 43775859)
129. Elkind MS. Impact of innate inflammation in population studies. Ann. NY Acad. Sci. 1207, 97-106 (2010).
130. Marsik C, Sunder-Plassmann R, Jilma B et al. The C-reactive protein (+)1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia. Clin. Chem. 52(10), 1952-1957 (2006). (Pubitemid 44470704)
131. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336(14), 973-979 (1997). (Pubitemid 27152782)
132. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98(8), 731-733 (1998). (Pubitemid 28391836)
133. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342(12), 836-843 (2000). (Pubitemid 30165206)
134. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347(20), 1557-1565 (2002). (Pubitemid 35315836)
135. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97(20), 2007-2011 (1998). (Pubitemid 28243661)
136. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297(6), 611-619 (2007).
137. Cao JJ, Thach C, Manolio TA et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 108(2), 166-170 (2003). (Pubitemid 36871298)
138. Wakugawa Y, Kiyohara Y, Tanizaki Y et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke 37(1), 27-32 (2006). (Pubitemid 43732043)
139. Makita S, Nakamura M, Satoh K et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis 204(1), 234-238 (2009).
140. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler. Thromb. Vasc. Biol. 20(4), 1047-1051 (2000). (Pubitemid 30207580)
141. Rost NS, Wolf PA, Kase CS et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32(11), 2575-2579 (2001). (Pubitemid 33055308)
142. Curb JD, Abbott RD, Rodriguez BL et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 107(15), 2016-2020 (2003). (Pubitemid 36506076)
143. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293(13), 1609-1616 (2005). (Pubitemid 40471791)
144. Elkind MS, Luna JM, Moon YP et al. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology 73(16), 1300-1307 (2009).
145. Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108(19), 2317-2322 (2003). (Pubitemid 37413536)
146. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 165(18), 2063-2068 (2005). (Pubitemid 41434580)
147. Greenland P, OMalley PG. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch. Intern. Med. 165(21), 2454-2456 (2005). (Pubitemid 41720004)
148. Kaptoge S, Di Angelantonio E, Lowe G et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375(9709), 132-140 (2010).
149. Wang TJ, Nam BH, Wilson PW et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 22(10), 1662-1667 (2002).
150. Schillinger M, Exner M, Mlekusch W et al. Inflammation and Carotid Artery - Risk for Atherosclerosis Study (ICARAS). Circulation 111(17), 2203-2209 (2005). (Pubitemid 40632436)
151. Chapman CM, Beilby JP, Mcquillan BM, Thompson PL, Hung J. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke 35(7), 1619-1624 (2004). (Pubitemid 38823636)
152. Rerkasem K, Shearman CP, Williams JA et al. C-reactive protein is elevated in symptomatic compared with asymptomatic patients with carotid artery disease. Eur. J. Vasc. Endovasc. Surg. 23(6), 505-509 (2002). (Pubitemid 41079401)
153. Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J. Vasc. Surg. 38(5), 1018-1024 (2003). (Pubitemid 37409637)
154. Van Dijk EJ, Prins ND, Vermeer SE et al. C-Reactive protein and cerebral small-vessel disease: the Rotterdam Scan study. Circulation 112(6), 900-905 (2005). (Pubitemid 41170078)
155. Andersson J, Johansson L, Ladenvall P et al. C-reactive protein is a determinant of first-ever stroke: prospective nested case-referent study. Cerebrovasc. Dis. 27(6), 544-551 (2009).
156. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N. Engl. J. Med. 344(19), 1450-1460 (2001). (Pubitemid 32402103)
157. Di Napoli M, Papa F. C-reactive protein and cerebral small-vessel disease: an opportunity to reassess small-vessel disease physiopathology? Circulation 112(6), 781-785 (2005). (Pubitemid 41170061)
158. Feigin VL, Rinkel GJ, Lawes CM et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke 36(12), 2773-2780 (2005).
159. Montaner J, Fernandez-Cadenas I, Molina CA et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 37(5), 1205-1210 (2006). (Pubitemid 43731863)
160. Cucchiara BL, Messe SR, Sansing L et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 40(7), 2332-2336 (2009).
161. Woodward M, Lowe GD, Campbell DJ et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 36(10), 2143-2147 (2005). (Pubitemid 41429235)
162. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch. Intern. Med. 166(19), 2073-2080 (2006). (Pubitemid 44631394)
163. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke 30(5), 981-985 (1999). (Pubitemid 29211614)
164. Arenillas JF, Alvarez-Sabin J, Molina CA et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 34(10), 2463-2468 (2003). (Pubitemid 37221964)
165. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32(1), 133-138 (2001). (Pubitemid 32063837)
166. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 33(10), 2459-2464 (2002).
167. Elkind MS, Leon V, Moon YP, Paik MC, Sacco RL. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke 40(10), 3233-3237 (2009).
168. Elkind MS, Coates K, Tai W, Paik MC, Boden-Albala B, Sacco RL. Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurol. 6, 37 (2006).
169. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 199(1), 3-11 (2008).
170. Bogaty P, Brophy JM, Boyer L et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch. Int. Med. 165(2), 221-226 (2005).
171. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3), 499-511 (2003). (Pubitemid 36158056)
172. Di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36(6), 1316-1329 (2005). (Pubitemid 40798763)
173. Alexandrova ML, Danovska MP. Serum C-reactive protein and lipid hydroperoxides in predicting short-term clinical outcome after spontaneous intracerebral hemorrhage. J. Clin. Neurosci. 18(2), 247-252 (2011).
174. Diedler J, Sykora M, Hahn P et al. C-reactive-protein levels associated with infection predict short- and long-term outcome after supratentorial intracerebral hemorrhage. Cerebrovasc. Dis. 27(3), 272-279 (2009).
175. Godoy DA, Papa F, Campi V et al. Relationship between baseline white blood cell and C-reactive protein with mortality in patients with spontaneous intracerebral hemorrhage. J. Neurol. Neurophysiol. 1, 104 (2010).
176. Di Napoli M, Godoy DA, Campi V et al. C-reactive protein level measurement improves mortality prediction when added to the spontaneous intracerebral hemorrhage score. Stroke 42(5), 1230-1236 (2011).
177. Libby P. Inflammation in atherosclerosis. Nature 420(6917), 868-874 (2002). (Pubitemid 36019640)
178. Willcox BJ, Abbott RD, Yano K, Rodriguez BL, Willcox DC, Curb JD. C-reactive protein, cardiovascular disease and stroke: new roles for an old biomarker. Expert Rev Neurother 4(3), 507-518 (2004). (Pubitemid 38607915)
179. Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res 50(Suppl.), S352-S357 (2009).
180. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102(18), 2165-2168 (2000).
181. Torzewski M, Rist C, Mortensen RF et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20(9), 2094-2099 (2000).
182. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106(12), 1439-1441 (2002).
183. Szalai AJ, Nataf S, Hu XZ, Barnum SR. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J. Immunol. 168(11), 5792-5797 (2002). (Pubitemid 34556165)
184. Hu XZ, Wright TT, Jones NR et al. Inhibition of experimental autoimmune encephalomyelitis in human C-reactive protein transgenic mice is FcgammaRIIB dependent. Autoimmune Dis. 2011, 484936 (2011).
185. Teupser D, Weber O, Rao TN, Sass K, Thiery J, Fehling HJ. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J. Biol. Chem. 286(8), 6272-6279 (2011).
186. Jones NR, Pegues MA, Mccrory MA et al. Collagen-induced arthritis is exacerbated in C-reactive protein deficient mice. Arthritis Rheum. 63(9), 2641-2650 (2011
187. Crowell RE, Du Clos TW, Montoya G, Heaphy E, Mold C. C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J. Immunol. 147(10), 3445-3451 (1991).
188. Marjon KD, Marnell LL, Mold C, Du Clos TW. Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia. J. Immunol. 182(3), 1397-1403 (2009).
189. Emsley HC, Smith CJ, Gavin CM et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J. Neuroimmunol. 139(1-2), 93-101 (2003). (Pubitemid 36694395)
190. Zhang J, Rui YC, Yang PY, Lu L, Li TJ. C-reactive protein induced expression of adhesion molecules in cultured cerebral microvascular endothelial cells. Life Sci. 78(26), 2983-2988 (2006).
191. Tuttolomondo A, Di Sciacca R, Di Raimondo D, Renda C, Pinto A, Licata G. Inflammation as a therapeutic target in acute ischemic stroke treatment. Curr. Top. Med. Chem. 9(14), 1240-1260 (2009).
192. Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J. Cereb. Blood Flow Metab. 24(11), 1214-1218 (2004). (Pubitemid 39482482)
193. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
194. Pepys MB, Hirschfield GM, Tennent GA et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440(7088), 1217-1221 (2006).
195. Craft TK, Glasper ER, Mccullough L et al. Social interaction improves experimental stroke outcome. Stroke 36(9), 2006-2011 (2005). (Pubitemid 41266542)
196. Mcgeer PL, Mcgeer EG, Yasojima K. Alzheimer disease and neuroinflammation. J. Neural Transm. Suppl. 59, 53-57 (2000). (Pubitemid 30479406)
197. Godoy DA, Pinero GR, Svampa S, Papa F, Di Napoli M. Early hyperglycemia and intravenous insulin-the rationale and management of hyperglycemia for spontaneous intracerebral hemorrhage patients: is time for change? Neurocrit. Care 10(1), 150-153 (2009).
198. Blake GJ, Ridker PM, Kuntz KM. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am. J. Med. 114(6), 485-494 (2003). (Pubitemid 36515111)
199. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107(3), 363-369 (2003). (Pubitemid 36158034)
200. Ess SM, Szucs TD. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy. Ital. Heart J. 2(3), 181-188 (2001). (Pubitemid 32409864)
201. Everett BM, Glynn RJ, Macfadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 121(1), 143-150 (2010).
202. De Lorgeril M, Salen P, Abramson J et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch. Int. Med. 170(12), 1032-1036 (2010).
203. Agrawal A, Hammond DJ Jr, Singh SK. Atherosclerosis-related functions of C-reactive protein. Cardiovasc. Hematol. Disord. Drug Targets 10(4), 235-240 (2010).
204. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113(17), 2128-2134; discussion 2151 (2006).
205. Verma S, Szmitko PE, Yeh ET. C-reactive protein: structure affects function. Circulation 109(16), 1914-1917 (2004). (Pubitemid 38544477)
206. Barna BP, Deodhar SD, Gautam S, Yen-Lieberman B, Roberts D. Macrophage activation and generation of tumoricidal activity by liposome-associated human C-reactive protein. Cancer Res. 44(1), 305-310 (1984 (Pubitemid 14177755)